The amount of collaboration agreements, development regulatory and commercial milestone payment.

No definition available.

Name:	gmab_CollaborationAgreementsDevelopmentRegulatoryAndCommercialMilestonePayment
Namespace Prefix:	gmab_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of upfront payment under collaboration agreement term.

+ References

No definition available.

+ Details

Name:	gmab_CollaborationAgreementsUpfrontPayment
Namespace Prefix:	gmab_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems
Namespace Prefix:	gmab_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

License exercisable term.

+ References

No definition available.

+ Details

Name:	gmab_LicenseExercisableTerm
Namespace Prefix:	gmab_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of options to obtain commercial licenses.

+ References

No definition available.

+ Details

Name:	gmab_NumberOfOptionsToObtainCommercialLicenses
Namespace Prefix:	gmab_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2019-01-01
-Paragraph 24
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2019-en-r&anchor=para_24_a&doctype=Standard
-URIDate 2019-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2019-01-01
-Paragraph B16
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2019-en-r&anchor=para_B16&doctype=Appendix&subtype=B
-URIDate 2019-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2019-01-01
-Paragraph 54
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_54_e&doctype=Standard
-URIDate 2019-03-27

+ Details

Name:	ifrs-full_InvestmentAccountedForUsingEquityMethod
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The proportion of ownership interest in a joint venture attributable to the entity. [Refer: Joint ventures [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2019-01-01
-Paragraph 17
-Subparagraph b
-Clause iii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2019-en-r&anchor=para_17_b_iii&doctype=Standard
-URIDate 2019-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2019-01-01
-Paragraph 16
-Subparagraph b
-Clause iii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2019-en-r&anchor=para_16_b_iii&doctype=Standard
-URIDate 2019-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2019-01-01
-Paragraph 21
-Subparagraph a
-Clause iv
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2019-en-r&anchor=para_21_a_iv&doctype=Standard
-URIDate 2019-03-27

+ Details

Name:	ifrs-full_ProportionOfOwnershipInterestInJointVenture
Namespace Prefix:	ifrs-full_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_CurevacCollaborationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

BASIS OF PRESENTATION - Collaboration Agreements (Details) € in Millions, kr in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2019 EUR (€)	Dec. 31, 2017	Dec. 31, 2019 Option	Dec. 31, 2019 USD ($)	Dec. 31, 2019 item	Dec. 31, 2019 DKK (kr)	Dec. 19, 2019 DKK (kr)
Collaboration Agreements
Ownership interest in joint venture		50.00%
Other investments \| kr						kr 149
Minimum
Collaboration Agreements
Collaborative arrangement, Development, Regulatory and commercial milestone payment				$ 275
Maximum
Collaboration Agreements
Collaborative arrangement, Development, Regulatory and commercial milestone payment				368
CureVac
Collaboration Agreements
Upfront Payment				10
Number of options			3		3
License exercisable term	5 years
Collaborative arrangement, Development, Regulatory and commercial milestone payment				280
Other investments	€ 20					kr 149	kr 149
CureVac \| Minimum
Collaboration Agreements
Collaborative arrangement, Development, Regulatory and commercial milestone payment				275
CureVac \| Maximum
Collaboration Agreements
Collaborative arrangement, Development, Regulatory and commercial milestone payment				$ 368